ResearcherShanxi Medical UniversityActive in the last 2 years

Runjie Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-1631-2170; OpenAlex author ID A5090234816. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2025: 2 papers

Papers 2

Tumor-associated macrophages (TAMs): Constructing an immunosuppressive microenvironment bridge for pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1016/j.cpt.2024.07.004 ↗
Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. Co-author DOI 10.1016/j.isci.2024.111693 ↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jianang Li · 2 shared papers, 2025 · strength 0.54
- Paper Tumor-associated macrophages (TAMs): Constructing an immunosuppressive microenvironment bridge for pancreatic ductal ad… DOI 10.1016/j.cpt.2024.07.004 ↗
- Paper Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. DOI 10.1016/j.isci.2024.111693 ↗
Liang Liu · 2 shared papers, 2025 · strength 0.54
- Paper Tumor-associated macrophages (TAMs): Constructing an immunosuppressive microenvironment bridge for pancreatic ductal ad… DOI 10.1016/j.cpt.2024.07.004 ↗
- Paper Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. DOI 10.1016/j.isci.2024.111693 ↗
Jinbin Jia · 1 shared paper, 2025 · strength 0.33
- Paper Tumor-associated macrophages (TAMs): Constructing an immunosuppressive microenvironment bridge for pancreatic ductal ad… DOI 10.1016/j.cpt.2024.07.004 ↗
Wenquan Wang · 1 shared paper, 2025 · strength 0.33
- Paper Tumor-associated macrophages (TAMs): Constructing an immunosuppressive microenvironment bridge for pancreatic ductal ad… DOI 10.1016/j.cpt.2024.07.004 ↗
Haokang Feng · 1 shared paper, 2025 · strength 0.21
- Paper Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. DOI 10.1016/j.isci.2024.111693 ↗
Xu Han · 1 shared paper, 2025 · strength 0.21
- Paper Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. DOI 10.1016/j.isci.2024.111693 ↗
Huaxiang Xu · 1 shared paper, 2025 · strength 0.21
- Paper Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. DOI 10.1016/j.isci.2024.111693 ↗
Hanlin Yin · 1 shared paper, 2025 · strength 0.21
- Paper Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. DOI 10.1016/j.isci.2024.111693 ↗
Hua Su · 1 shared paper, 2025 · strength 0.21
- Paper Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. DOI 10.1016/j.isci.2024.111693 ↗
Lei Zhang · 1 shared paper, 2025 · strength 0.21
- Paper Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. DOI 10.1016/j.isci.2024.111693 ↗
Yuquan Guo · 1 shared paper, 2025 · strength 0.21
- Paper Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. DOI 10.1016/j.isci.2024.111693 ↗
Wenhui Lou · 1 shared paper, 2025 · strength 0.21
- Paper Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. DOI 10.1016/j.isci.2024.111693 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.